Want to see IN:SANOFI full AI Analyst Report?
SANOFI Stock Chart & Stats
₹3387.70
-₹20.10(-0.59%)
At close: 4:00 PM EDT
₹3387.70
-₹20.10(-0.59%)
Day’s Range― - ―
52-Week Range₹3,057.60 - ₹5,414.00
Previous CloseN/A
Volume9.67K
Average Volume (3M)3.77K
Market Cap
₹76.46B
Enterprise Value₹91.66K
Total Cash (Recent Filing)₹2.75B
Total Debt (Recent Filing)₹178.00M
Price to Earnings (P/E)24.7
Beta0.70
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.71%
Share Statistics
EPS (TTM)98.01
Shares Outstanding23,030,000
10 Day Avg. Volume3,778
30 Day Avg. Volume3,766
Financial Highlights & Ratios
PEG Ratio6.96
Price to Book (P/B)12.56
Price to Sales (P/S)5.12
P/FCF Ratio22.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)168.05
Revenue Forecast (FY)₹19.50B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low debt-to-equity (~1–2%) provides lasting financial flexibility and resilience. Over a multi-month horizon this reduces refinancing risk, supports steady dividend or buyback capacity, enables opportunistic M&A or investment, and cushions against sector shocks without eroding cash flow.
Strong Cash GenerationHigh FCF that closely matches net income and a sharp 2025 FCF increase (+53.7%) indicate durable earnings quality and cash conversion. This supports sustained reinvestment in sales/marketing or R&D, funds dividends and capex internally, and lowers reliance on external financing.
High Operating ProfitabilityConsistently strong EBIT (22–25%) and healthy net margins provide a durable profitability base. These margins create a buffer against revenue volatility, enable ongoing investment in core therapeutic franchises, and support sustained return on equity even amid cyclical pressures.
Bears Say
Weakened Revenue TrendA declining and inconsistent top line constrains long-term growth optionality. Persistent revenue weakness reduces operating leverage, limits scale benefits, forces margin reliance on cost cuts, and signals potential competitive, pricing, or portfolio issues that impair durable earnings growth.
Material Gross Margin CompressionA large drop in gross margin (~55–56% to ~39%) suggests structural pressures such as pricing erosion, cost inflation, or increased generic competition. Sustained margin loss materially reduces core earnings power and limits the company's ability to finance reinvestment without cutting costs or raising prices.
Decline In Equity BaseA notable fall in equity between 2023–2025 raises questions on capital returns or balance-sheet actions. Unexplained equity reduction can mask underlying weaknesses, reduce capital buffers, and create governance and capital-allocation uncertainty, limiting flexibility for strategic investments.
Sanofi India Limited News
SANOFI FAQ
What was Sanofi India Limited’s price range in the past 12 months?
Sanofi India Limited lowest stock price was ₹3057.60 and its highest was ₹5414.00 in the past 12 months.
What is Sanofi India Limited’s market cap?
Sanofi India Limited’s market cap is ₹76.46B.
When is Sanofi India Limited’s upcoming earnings report date?
Sanofi India Limited’s upcoming earnings report date is Oct 29, 2026 which is in 84 days.
How were Sanofi India Limited’s earnings last quarter?
Sanofi India Limited released its earnings results on Aug 04, 2026. The company reported ₹36.3 earnings per share for the quarter, missing the consensus estimate of ₹39.3 by -₹3.
Is Sanofi India Limited overvalued?
According to Wall Street analysts Sanofi India Limited’s price is currently Overvalued.
Does Sanofi India Limited pay dividends?
Sanofi India Limited pays a Semiannually dividend of ₹48 which represents an annual dividend yield of 3.71%. See more information on Sanofi India Limited dividends here
What is Sanofi India Limited’s EPS estimate?
Sanofi India Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sanofi India Limited have?
Sanofi India Limited has 23,030,000 shares outstanding.
What happened to Sanofi India Limited’s price movement after its last earnings report?
Sanofi India Limited reported an EPS of ₹36.3 in its last earnings report, missing expectations of ₹39.3. Following the earnings report the stock price went up 0.207%.
Which hedge fund is a major shareholder of Sanofi India Limited?
Currently, no hedge funds are holding shares in IN:SANOFI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, epilepsy, anti-infectives, and central nervous system, as well as allergy, pain care, digestive, and nutritional health under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products to approximately 24 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
Technical Analysis
Abbott India Limited
―
Cipla Ltd
―
Gland Pharma Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
PFIZER LIMITED
―